申请人:Pfizer Inc.
公开号:US05039672A1
公开(公告)日:1991-08-13
Certain spirocyclic heterocyclic compounds, and their pharmaceutically-acceptable salts, are inhibitors of the aldose reductase enzyme, and so are useful for the control of diabetic complications. Exemplary compounds include compounds of the formula ##STR1## wherein Y is ##STR2## X is --O-- or ##STR3## R.sub.1 and R.sub.2 are each independently H, alkyl C.sub.1 -C.sub.6,aryl or arylalkyl (C.sub.1 -C.sub.6); W.sub.1 and W.sub.2 are each independently hydrogen, halogen or nitro; and the pharmaceutically acceptable base addition salts thereof.
某些螺环杂环化合物及其药用盐是醛糖还原酶酶的抑制剂,因此对于控制糖尿病并发症是有用的。示例化合物包括符号##STR1##的化合物,其中Y是##STR2##,X是--O--或##STR3##,R.sub.1和R.sub.2分别独立地为H、烷基C.sub.1-C.sub.6、芳基或芳基烷基(C.sub.1-C.sub.6);W.sub.1和W.sub.2分别独立地为氢、卤素或硝基;以及其药用可接受的碱盐。